ResultsIQ

ResultsIQ › Latest results › Aeroflex Industries Limited

Aeroflex Industries Limited Q3 FY26 earnings call summary

NSE: AEROFLEX · BSE: 543972

Earnings call of 29 Jan 2026, summarised by AI from the filing.

Aeroflex reported highest ever quarterly revenue of ₹121 cr (+21% Y-o-Y) and EBITDA of ₹28.5 cr in Q3 FY26, with liquid cooling first dispatch and capacity expansion to 15,000 units by June 2026.

Key takeaways

  1. Guidance EBITDA margin expected in 23% to 25% range over next couple of years; target 25%.
  2. Capacity Added 1 million meters hose capacity, total 17.5 million meters; balance 2.5 million meters by Q2 FY27.

Original filing on BSE

Aeroflex Industries Limited Q1 FY27 results

As filed: Revenue ₹145 cr (+73% year on year), EBITDA ₹33.5 cr (+109% year on year), PAT ₹18.8 cr (+168% year on year), EBITDA margin 23.0% (+398 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹126 cr (+37% year on year), EBITDA ₹30.0 cr (+58% year on year), PAT ₹17.6 cr (+60% year on year), EBITDA margin 23.9% (+321 bps). Score 87 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 321 bps year on year. Revenue rose ₹33.8 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: +38.2% in 30 days (Nifty 500: −1.4%).
  • Q3 FY26: Revenue ₹121 cr (+21% year on year), EBITDA ₹28.3 cr (+29% year on year), PAT ₹16.5 cr (+10% year on year), EBITDA margin 23.4% (+144 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 144 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +42.5% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹111 cr (+17% year on year), EBITDA ₹26.0 cr (+30% year on year), PAT ₹14.0 cr (0% year on year), EBITDA margin 23.4% (+237 bps). Score 79 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 237 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹16.0 cr on a year ago, more than the ₹11.0 cr it added the year before. Share price after the results: −1.7% in 30 days (Nifty 500: +0.6%).
  • Q1 FY26: Revenue ₹84.0 cr (−7% year on year), EBITDA ₹16.0 cr (−11% year on year), PAT ₹7.0 cr (−42% year on year), EBITDA margin 19.1% (−95 bps). Score 12 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 95 bps year on year. Revenue fell 9% from last quarter. Share price after the results: −14.5% in 29 days (Nifty 500: −0.3%).
  • Q4 FY25: Revenue ₹92.0 cr (+18% year on year), EBITDA ₹19.0 cr (+27% year on year), PAT ₹11.0 cr (+10% year on year), EBITDA margin 20.7% (+142 bps). Score 64 of 100, In line with trend. EBITDA margin rose 142 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter. Share price after the results: −5.6% in 30 days (Nifty 500: +3.5%).
  • Q3 FY25: Revenue ₹100 cr (+37% year on year), EBITDA ₹22.0 cr (+57% year on year), PAT ₹15.0 cr (+67% year on year), EBITDA margin 22.0% (+282 bps). Score 95 of 100, Above trend. EBITDA margin rose 282 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹95.0 cr (+13% year on year), EBITDA ₹20.0 cr (+11% year on year), PAT ₹14.0 cr (+17% year on year), EBITDA margin 21.1% (−38 bps). Score 53 of 100, In line with trend. EBITDA margin fell 38 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Aeroflex Industries Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.